Financial Modeling Prep·2026-03-31 05:00Core Viewpoint - Kezar Life Sciences has agreed to be acquired by Aurinia Pharmaceuticals amid ongoing financial difficulties, with the deal structured to provide cash and contingent value rights to shareholders [1][2]. Acquisition Details - The acquisition agreement, announced on March 30, 2026, stipulates that Kezar shareholders will receive $6.95 in cash per share plus one non-transferable contingent value right (CVR) [2]. - The transaction will be executed as a tender offer expected to launch by April 13, 2026, followed by a merger, contingent on several conditions including a majority of outstanding shares being tendered and Kezar having at least $50 million in closing net cash [2]. - The deal is anticipated to close in the second quarter of 2026 and has received unanimous approval from Kezar's board, supported by key investor Tang Capital Partners [2]. Shareholder Investigations - Law firms Ademi LLP and Halper Sadeh LLC are investigating the acquisition to determine if Kezar's board breached fiduciary duties and whether the best possible price was obtained for shareholders [3]. Financial Performance - For the year ended December 31, 2025, Kezar reported a net loss of approximately $56.0 million, an improvement from $83.7 million in 2024, with an operating loss of $59.1 million [4]. - In Q4 2025, Kezar posted an EPS of -$1.99, missing analyst consensus estimates of around -$1.39, and the company has no commercial revenue [4]. - Kezar maintains a cash runway supported by prior cost-cutting measures, including workforce reductions, and held substantial cash reserves previously reported in the $70–90 million range [4][5]. Market Reaction and Strategic Context - Following the acquisition announcement, KZR shares surged approximately 19–21%, trading around $7.45, reflecting a premium to the $6.95 cash offer due to CVR value and deal uncertainty [6]. - The acquisition allows Aurinia to expand its autoimmune disease portfolio by adding zetomipzomib, which has shown promising clinical data and positive FDA interactions [6]. Additional Provisions - The agreement includes provisions that may deter or penalize competing offers, a common feature in such transactions [7]. - The CVR may provide additional payments tied to ongoing clinical development of Kezar's lead candidate zetomipzomib and other financial arrangements [8].